Barclays’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
Barclays's PCRX Position: Q3 2026 in Review
Barclays increased its Pacira BioSciences (PCRX) stake by 15% in Q3 2026, buying an estimated $1.15M and bringing the position to 355,514 shares worth $8.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1708.
Barclays first reported a position in PCRX in Q2 2013 and has held it in 54 quarters since. The position peaked at $12.3M in Q1 2017. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.
- Barclays held 355,514 shares of Pacira BioSciences worth $8.91M as of Q3 2026.
- Barclays bought 45,325 Pacira BioSciences shares in Q3 2026, an estimated $1.15M.
- Pacira BioSciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1708 holding.
- Barclays first reported a position in Pacira BioSciences in Q2 2013 and has held it in 54 quarters since.
- Barclays's Pacira BioSciences position peaked at $12.3M in Q1 2017.
- 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.